MURA Research | Milton Maxwell

MURA

Mural Oncology plc

2.0400

+2.0400+0%

Dec 4, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

35.38M

P/E (TTM)

Basic EPS (TTM)

-6.93

Dividend Yield

Recent Filings

8-K

12/5/25Dec 5, 2025

10-Q

11/6/25Nov 6, 2025

8-K

Shareholders greenlight Mural acquisition

10/24/25Oct 24, 2025

Mural Oncology shareholders overwhelmingly approved the scheme of arrangement on October 24, 2025, paving the way for XOMA Royalty's acquisition via its subsidiary. With over 99% support at both the Scheme Meeting and EGM, the deal advances under Irish law. Closing is targeted for Q4 2025, pending High Court sanction and customary conditions. Yet risks linger if approvals falter.

8-K

Mural Oncology acquisition announced

8/20/25Aug 20, 2025

Mural Oncology agreed to a $2.035 base cash acquisition by XOMA Royalty's subsidiary on August 20, 2025, with potential upside to $2.24 per share if closing net cash exceeds $36.2 million estimates. This follows a strategic review after halting nemvaleukin development, valuing the firm at ~$36.2 million and offering a 13.1% premium to the prior close. Post-close, XOMA plans an orderly wind-down of operations. Shareholder approval and court sanction remain key hurdles.

8-K

Mural's Q2 loss widens amid cuts

8/4/25Aug 4, 2025

Mural Oncology reported Q2 2025 net loss of $48.0 million, up from $31.6 million last year, driven by $17.5 million in restructuring charges after slashing its workforce by 90% and halting all R&D on nemvaleukin alfa and other programs. Cash stood at $77.1 million as of June 30, with estimates of $43-48 million by year-end absent a strategic deal. The company persists in seeking alternatives to maximize shareholder value. No transaction is assured.

About

Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. As of December 4, 2025, Mural Oncology plc operates as a subsidiary of XOMA Royalty Corporation.

CEO

Ms. Caroline J. Loew Ph.D.

IPO

11/16/2023

Website

https://www.muraloncology.com

Employees

116

Sector

Healthcare

Industry

Biotechnology